Study of NEO-201 in Solid Tumors Expansion Cohorts
Status:
Recruiting
Trial end date:
2025-10-15
Target enrollment:
Participant gender:
Summary
The open label, first-in-human, phase 1, dose escalation component in refractory solid tumors
has been completed. The Maximum Tolerated Dose and Recommended Phase 2 Dose (RP2D) was
determined to be 1.5mg/kg.
The Expansion Phase of this study is currently enrolling subjects with non small cell lung
cancer (NSCLC), head and neck squamous cell carcinoma (HNSCC), cervical and uterine cancers
who progressed on front line therapy. Subjects will be treated with NEO-201 at the RP2D (1.5
mg/kg) every 2 weeks in combination with pembrolizumab, given 1 day after the NEO-201, at 400
mg IV every 6 weeks.